申请人:Merck & Co., Inc.
公开号:US04704462A1
公开(公告)日:1987-11-03
Substituted 2,3,3a,6-tetrahydro-6-oxobenzofuran derivatives have been prepared. These neolignans are found to have potent and specific PAF (Platelet-Activating-Factor) antagonistic activities and thereby useful in the treatment of various diseases or disorders mediated by PAF, for example, pain, fever, inflammation, cardiovascular disorder, asthma, lung edema, allergic disorders, skin diseases, psoriasis, toxic shock syndrome and adult respiratory distress syndrome.
已经制备了取代的2,3,3a,6-四氢-6-氧代苯并呋喃衍生物。这些新木脂素具有强效和特异性的PAF(血小板活化因子)拮抗活性,因此在治疗各种由PAF介导的疾病或疾病中有用,例如疼痛,发热,炎症,心血管疾病,哮喘,肺水肿,过敏性疾病,皮肤病,牛皮癣,毒性休克综合征和成人呼吸窘迫综合征。